Two senators wrote a letter. Somewhere, a man with a Robinhood tattoo just learned what an "endpoint" is.
Angela Alsobrooks and Ron Wyden want to know what Health Secretary Robert F. Kennedy Jr.'s department is doing about prediction markets on clinical trials and FDA approvals. Kalshi and Polymarket let users trade on whether experimental drugs for weight loss, Alzheimer's and several cancers get approved.
Read that again. Strangers wager on whether your grandmother's dementia drug works.
The senators say this "undermines the scientific process" and "harms trial participants." Fair. But consider the trader. He has a 10-K he didn't read and a chart he drew with a ruler. He is now handicapping double-blind studies.
Kalshi says it lists only late-stage trials. It opens contracts only after enrollment closes. It uses employee verification technology.
Employee verification. For a market where the only people who know anything are employees.
The senators also want every internal HHS communication about staff trading these contracts. Imagine that inbox. "Quick question. Is a p-value of 0.049 a yes or a no? Asking for my Kalshi account."
The letter also demands HHS correspondence with the platforms and the Commodity Futures Trading Commission. Expect a reply by the heat death of the universe, notarized.
My analysis is simple. Every chart is a Rorschach test. Now the ink blot is a monoclonal antibody. You are not predicting anything. You are guessing which of 400 anonymous patients got the sugar pill.
The real insider is a nurse in Ohio who knows who got the placebo. She makes $38 an hour. Somebody should tell her.
Retail traders finally found a market where they can lose money and endanger public health. Efficiency.
Photo by Bernd 📷 Dittrich on Unsplash

Leave a Comment